Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | Director | March 11, 2026 | March 13, 2026 |
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Director · President and CEO | October 06, 2026 | October 08, 2026 |
| Xencor IncXNCR · Entity 4487 | Director | June 23, 2022 | June 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENANTA PHARMACEUTICALS INC
Report date March 11, 2026 · Filed March 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2036-03-11 | Direct | 20,000 |
Reported balance
After 2026-03-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-11 · Grant · Acquired 20,000 · Balance 20,000 F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.
IDEAYA Biosciences, Inc.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 690,695 |
Ending reported balance
After 2026-10-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 26,338 · Balance 717,033 Row 2 · 2026-10-06 · Sale · Disposed 25,538 · Balance 691,495 F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on July 7, 2026, in which the majority of the shares acquired upon the exercise of stock options were granted to the Reporting Person prior to the Issuer's initial public offering and are approaching their expiration date. F2: This transaction was executed in multiple trades in prices ranging from $37.00 to $37.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-10-06 · Sale · Disposed 800 · Balance 690,695 F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on July 7, 2026, in which the majority of the shares acquired upon the exercise of stock options were granted to the Reporting Person prior to the Issuer's initial public offering and are approaching their expiration date. F3: This transaction was executed in multiple trades in prices ranging from $38.23 to $38.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2028-02-26 | Direct | 23,116 |
Reported balance
After 2026-10-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-06 · Exercise / conversion · Disposed 26,338 · Balance 23,116 F4: The shares subject to the option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on July 7, 2026, in which the majority of the shares acquired upon the exercise of stock options were granted to the Reporting Person prior to the Issuer's initial public offering and are approaching their expiration date.
F2: This transaction was executed in multiple trades in prices ranging from $37.00 to $37.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: This transaction was executed in multiple trades in prices ranging from $38.23 to $38.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4: The shares subject to the option are fully vested and exercisable.
Xencor Inc
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.58 · Expires 2032-06-23 | Direct | 21,412 |
Reported balance
After 2022-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 21,412 · Balance 21,412 F1: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 23, 2022, such that the total number of shares will be fully vested on June 23, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 23, 2022, such that the total number of shares will be fully vested on June 23, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 23:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 26,338 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001610717-26-000434 · form4.xml · derivative · entry 4 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,116 Underlying: Common Stock · 26,338 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 23:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 800 | $38.26 | $30,610.08 |
DisclosureSEC source: 0001610717-26-000434 · form4.xml · nonDerivative · entry 3 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 690,695 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on July 7, 2026, in which the majority of the shares acquired upon the exercise of stock options were granted to the Reporting Person prior to the Issuer's initial public offering and are approaching their expiration date. F3 · price: This transaction was executed in multiple trades in prices ranging from $38.23 to $38.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 23:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 25,538 | $37.39 | $954,786.65 |
DisclosureSEC source: 0001610717-26-000434 · form4.xml · nonDerivative · entry 2 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 691,495 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on July 7, 2026, in which the majority of the shares acquired upon the exercise of stock options were granted to the Reporting Person prior to the Issuer's initial public offering and are approaching their expiration date. F2 · price: This transaction was executed in multiple trades in prices ranging from $37.00 to $37.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 23:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 26,338 | $4.31 | $113,516.78 |
DisclosureSEC source: 0001610717-26-000434 · form4.xml · nonDerivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 717,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:17 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0002064832-26-000140 · form4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-03-11 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 19:58 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $32.19 | $0.00 |
DisclosureSEC source: 0001610717-26-000034 · form4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2036-01-30 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 21:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 15,700 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001062993-25-005504 · form4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2035-03-13 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 18:00 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $20.24 | $0.00 |
DisclosureSEC source: 0001610717-25-000038 · form4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2035-02-26 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 06:00 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 12,808 | $0.00 Strike: $19.52 | $0.00 |
DisclosureSEC source: 0001610717-25-000021 · form4.xml · derivative · entry 2 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,192 Underlying: Common Stock · 12,808 shares Expires 2031-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 06:00 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 12,808 | $19.52 | $250,012.16 |
DisclosureSEC source: 0001610717-25-000021 · form4.xml · nonDerivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 690,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 34,433 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · derivative · entry 13 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,454 Underlying: Common Stock · 34,433 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| May 16, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 4,349 | $42.37 | $184,249.73 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · nonDerivative · entry 10 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 677,887 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 22, 2023. F8 · price: This transaction was executed in multiple trades in prices ranging from $42.26 to $42.595, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 16, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 30,084 | $41.73 | $1,255,504.60 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · nonDerivative · entry 9 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 682,236 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 22, 2023. F7 · price: This transaction was executed in multiple trades in prices ranging from $41.2651 to $42.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 16, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 34,433 | $4.31 | $148,406.23 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · nonDerivative · entry 8 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 712,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 83,856 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · derivative · entry 12 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,887 Underlying: Common Stock · 83,856 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| May 15, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 503 | $44.12 | $22,191.30 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · nonDerivative · entry 7 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 677,887 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 22, 2023. F6 · price: This transaction was executed in multiple trades in prices ranging from $44.10 to $44.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 15, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 29,761 | $43.48 | $1,293,933.88 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · nonDerivative · entry 6 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 678,390 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 22, 2023. F5 · price: This transaction was executed in multiple trades in prices ranging from $43.09 to $43.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 15, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 53,592 | $42.57 | $2,281,631.17 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · nonDerivative · entry 5 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 708,151 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 22, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $42.08 to $43.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 15, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 83,856 | $4.31 | $361,419.36 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · nonDerivative · entry 4 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 761,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 56,711 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · derivative · entry 11 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,743 Underlying: Common Stock · 56,711 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| May 14, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 2,303 | $41.84 | $96,347.62 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · nonDerivative · entry 3 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 677,887 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 22, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $41.81 to $41.945, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 14, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 54,408 | $41.60 | $2,263,432.65 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · nonDerivative · entry 2 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 680,190 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 22, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $40.815 to $41.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 14, 2024 Filed May 16, 2024 17:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 56,711 | $4.31 | $244,424.41 |
DisclosureSEC source: 0001610717-24-000239 · form4.xml · nonDerivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 734,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:19 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 15,700 | $0.00 Strike: $15.66 | $0.00 |
DisclosureSEC source: 0001062993-24-006042 · form4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2034-03-06 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 17:28 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 480,000 | $0.00 Strike: $46.22 | $0.00 |
DisclosureSEC source: 0001610717-24-000120 · form4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 480,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 16:27 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 23,557 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001610717-24-000053 · form4.xml · derivative · entry 6 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 224,454 Underlying: Common Stock · 23,557 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 16:27 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 23,557 | $45.54 | $1,072,715.11 |
DisclosureSEC source: 0001610717-24-000053 · form4.xml · nonDerivative · entry 4 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 677,887 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $45.01 to $45.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 16:27 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 23,557 | $4.31 | $101,530.67 |
DisclosureSEC source: 0001610717-24-000053 · form4.xml · nonDerivative · entry 3 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 701,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 16:27 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 75,815 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001610717-24-000053 · form4.xml · derivative · entry 5 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 248,011 Underlying: Common Stock · 75,815 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 16:27 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 75,815 | $45.15 | $3,422,834.97 |
DisclosureSEC source: 0001610717-24-000053 · form4.xml · nonDerivative · entry 2 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 677,887 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $45.00 to $45.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 16:27 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 75,815 | $4.31 | $326,762.65 |
DisclosureSEC source: 0001610717-24-000053 · form4.xml · nonDerivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 753,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 18:05 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 628 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001610717-24-000043 · form4.xml · derivative · entry 4 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 323,826 Underlying: Common Stock · 628 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 18:05 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 4 | $45.01 | $180.04 |
DisclosureSEC source: 0001610717-24-000043 · form4.xml · nonDerivative · entry 3 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 677,887 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 18:05 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 624 | $45.00 | $28,080.00 |
DisclosureSEC source: 0001610717-24-000043 · form4.xml · nonDerivative · entry 2 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 677,891 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 18:05 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 628 | $4.31 | $2,706.68 |
DisclosureSEC source: 0001610717-24-000043 · form4.xml · nonDerivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 678,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 17:40 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 62,739 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001610717-24-000028 · form4.xml · derivative · entry 6 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 324,454 Underlying: Common Stock · 62,739 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 17:40 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 62,739 | $40.17 | $2,519,968.40 |
DisclosureSEC source: 0001610717-24-000028 · form4.xml · nonDerivative · entry 4 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 677,887 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $40.00 to $40.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 17:40 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 62,739 | $4.31 | $270,405.09 |
DisclosureSEC source: 0001610717-24-000028 · form4.xml · nonDerivative · entry 3 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 740,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 17:40 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 12,261 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001610717-24-000028 · form4.xml · derivative · entry 5 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 387,193 Underlying: Common Stock · 12,261 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 17:40 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 12,261 | $40.04 | $490,913.27 |
DisclosureSEC source: 0001610717-24-000028 · form4.xml · nonDerivative · entry 2 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 677,887 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $40.00 to $40.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 17:40 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 12,261 | $4.31 | $52,844.91 |
DisclosureSEC source: 0001610717-24-000028 · form4.xml · nonDerivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 690,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 17:34 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001610717-23-000405 · form4.xml · derivative · entry 3 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 399,454 Underlying: Common Stock · 75,000 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 17:34 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 75,000 | $35.03 | $2,627,617.50 |
DisclosureSEC source: 0001610717-23-000405 · form4.xml · nonDerivative · entry 2 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 677,887 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $35.00 to $35.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 17:34 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 75,000 | $4.31 | $323,250.00 |
DisclosureSEC source: 0001610717-23-000405 · form4.xml · nonDerivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 752,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2023 Filed Apr 13, 2023 16:11 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 11,601 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001610717-23-000007 · form4.xml · derivative · entry 2 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,454 Underlying: Common Stock · 11,601 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| April 12, 2023 Filed Apr 13, 2023 16:11 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 11,601 | $4.31 | $50,000.31 |
DisclosureSEC source: 0001610717-23-000007 · form4.xml · nonDerivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 677,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 22:18 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 10,800 | $0.00 Strike: $47.72 | $0.00 |
DisclosureSEC source: 0001062993-23-006091 · form4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2033-03-02 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2023), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2024 annual meeting of stockholders. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 16:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001567619-23-003944 · doc1.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 16:53 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 21,412 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001127602-22-018174 · form4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,412 Underlying: Common Stock · 21,412 shares Expires 2032-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 23, 2022, such that the total number of shares will be fully vested on June 23, 2023. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:45 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $68.22 | $0.00 |
DisclosureSEC source: 0001062993-22-007005 · form4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2032-03-03 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 3, 2022), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2023 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.